Real-world results of first-line axitinib/axitinib combined with avelumab in renal cell carcinoma

The application of first-line avelumab (Avelumab) combined with axitinib/axitinib (Axitinib) in patients with advanced renal cell carcinoma (RCC) has received widespread attention in recent years. According to the results of the phase 3 JAVELIN Renal 101 trial (NCT02684006), the combination treatment of axitinib plus avacizumab showed significant advantages in effectiveness compared with the traditional targeted therapy sunitinib. The study showed that this combination therapy not only prolonged progression-free survival (PFS), but also significantly improved objective response rates (ORRs), which laid the foundation for its clinical application.

FurtherAVION studies provide real-world data to validate these findings. As of the data cutoff on July 5, 2024, the median overall survival rate (OS) of the axitinib combined with avacizumab group in this study has not yet been reached, but the 6-month and 12-month OS rates were 89.1% (95% CI, 81.2%-93.8%) and 82.7% (95% CI, 73.5%-88.9%) respectively. These data demonstrate the good survival effect of this combination in actual clinical practice.

It should be noted thatthe patient population in the AVION study reflects real-world conditions and includes some individuals with poor prognosis. This is crucial because it makes the research results more representative and can effectively guide clinical decision-making. In the study, the median PFS was 11.3 months (95% CI 8.1 - not evaluable). This data is consistent with the results in the JAVELIN Renal 101 trial and further proves the effectiveness of the combination regimen.

In terms of efficacy,The ORR of the AVION study was 46% (95%CI, 35.2%-57.0%), while the disease control rate (DCR) reached 79.3% (95%CI, 69.3%-87.3%). These results show that most patients can achieve good therapeutic effects after receiving this therapy. Safety is an important metric in evaluating any treatment regimen. The AVION study showed that the safety profile of this regimen was controllable, with a low frequency of grade 3 or higher toxicities. This is consistent with the good tolerability observed in the pivotal trial and provides clinicians with confidence when using this combination.

In summary,The consistency between AVION's real-world data and the JAVELIN Renal 101 trial undoubtedly supports the clinical utility of axitinib combined with avalizumab in different patient populations, especially those with poor prognostic factors. Therefore, this treatment option is gradually regarded as a standard care option for advanced renal cell carcinoma, marking a new stage in the treatment of renal cell carcinoma and bringing hope to more patients.

References:https://www.onclive.com/view/dr-merseburger-on-real-world-outcomes-with-first-line-axitinib-plus-avelumab-in-rcc